AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04997941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: The surgery date should be fixed before randomization. The surgery is to be performed within 1 day after the last dose of study treatment.
Study NCT06187493 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: lisinopril, enalapril
Description: 1. Both arms should aim to achieve optimal blood pressure control, typically defined as a systolic blood pressure below 130 mmHg and a diastolic blood pressure below 80 mmHg. This can be achieved through lifestyle modifications, additional medications, or a combination of both.~2. Maintaining good glycemic control is also important for both arms. This can be achieved through diet, exercise, and diabetes medications.~3. Both arms may also receive other supportive care measures for DKD, such as protein restriction, dietary counseling, and management of other co-morbidities like anemia and hyperlipidemia.
Study NCT06187493 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: dapagliflozin, empagliflozin
Description: 1. Both arms should aim to achieve optimal blood pressure control, typically defined as a systolic blood pressure below 130 mmHg and a diastolic blood pressure below 80 mmHg. This can be achieved through lifestyle modifications, additional medications, or a combination of both.~2. Maintaining good glycemic control is also important for both arms. This can be achieved through diet, exercise, and diabetes medications.~3. Both arms may also receive other supportive care measures for DKD, such as protein restriction, dietary counseling, and management of other co-morbidities like anemia and hyperlipidemia.
Study NCT05172466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BeCare application
Description: Participants will complete activities on the application 3 times a week for 2 weeks when they first join the study. They will then attend 4 in-person visits where they complete clinical and application based assessments. Activities are clearly marked in the application and participants are assigned specific assessments by the study team. The application analyzes user input during each evaluation to provide an outcome measure for that assessment.
Study NCT06169163 — intervention group
Intervention type: OTHER
Intervention: Exhaled breath sampling
Description: Participants will maintain a clear fluid diet for a minimum of 6 hours prior to breath collection. Participants will be asked to provide a breath sample by exhaling into single-use breath collection bags. Using a custom designed gas sampling pump, the breath VOCs will be transferred onto TD tubes at a controlled flow rate. This breath sampling procedure will be repeated once. When the participants' breath sampling is complete, room air (Blank) samples must be taken onto additional TD tubes using the same procedure. The TD tubes will be sealed with long-term storage caps using the CapLok Tool.
Study NCT05301413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Tailored Diabetes Prevention Program
Description: This intervention includes a culturally tailored DPP curriculum, class procedures, and handouts
Study NCT04914156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic based dietary advice
Description: Genetic test results for 70 genes relating to nutrition and physical activity will be used in conjunction with participants current dietary intake to create nutrition advice tailored to each individual.
Study NCT04914156 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personalised population based dietary advice
Description: Current dietary intake will be compared with current best practice population-based sports nutrition dietary advice to create tailored nutrition advice for each of the participants
Study NCT06507579 — intervention group
Intervention type: DEVICE
Intervention: Hydra transcatheter aortic valve (THV) series
Description: The Hydra device consists of a self-expanding nitinol frame and three bovine pericardial leaflets in supra-annular position.
Study NCT05222399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3871801
Description: Administered orally.
Study NCT05301413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Tailored DPP Enhanced with Socioeconomic Supports
Description: This intervention includes the culturally tailored DPP curriculum, class procedures, and handouts along with promotional items for class participation, opportunities to attend class in-person or virtually through a digital platform, and assistance from a community health worker to provide linkage to health care services and community resources
Study NCT05301413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program
Description: This is the CDC TD2 evidence-based Diabetes Prevention Program
Study NCT06484634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Description: A daily dose of 40 mg of low-molecular-weight heparin (LMWH) subcutaneously was given to the patients.
Study NCT04701112 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Temporary His bundle pacing
Description: Temporary use of a Medtronic 3830 electrode placed in the region of His bundle, in combination with a Medtronic 5392 dual chamber external pacemaker and a temporary Edwards D200F7 Swan Ganz Pacing -catheter with atrial pacing capability.~AV synchronous pacing (DDD 60/minute during rest and 120/minute during exercise, AV delay 150/180ms) will be performed using the atrial port (pacing catheter atrial electrodes) and ventricular port (His bundle electrode), or in the case of atrial fibrillation, only pacing the the His bundle in VVI mode 60/minute during rest and 120/minute during exercise.~The Swan-Ganz will then be used for hemodynamic measurements during pacing. A Cardiotek ECG system will be used for simultaneous 12 lead ECG registration.
Study NCT04701112 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Temporary His bundle pacing
Description: Temporary use of a Medtronic 3830 electrode placed in the region of His bundle, in combination with a Medtronic 5392 dual chamber external pacemaker and a temporary Edwards D200F7 Swan Ganz Pacing -catheter with atrial pacing capability.~AV synchronous pacing (DDD 60/minute during rest and 120/minute during exercise, AV delay 150/180ms) will be performed using the atrial port (pacing catheter atrial electrodes) and ventricular port (His bundle electrode), or in the case of atrial fibrillation, only pacing the the His bundle in VVI mode 60/minute during rest and 120/minute during exercise.~The Swan-Ganz will then be used for hemodynamic measurements during pacing. A Cardiotek ECG system will be used for simultaneous 12 lead ECG registration.
Study NCT05301413 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Prevention Program
Description: This is the CDC TD2 evidence-based Diabetes Prevention Program
Study NCT05619120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mexiletine
Description: Mexiletine (150mg, bid, po) is given to patients who have been divided into Mexiletine group.
Study NCT05619120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional therapy
Description: Treatment according to the guidelines for the management of ventricular arrhythmias (2017 AHA/ACC/HRS)
Study NCT05619120 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Treatment according to the guidelines for the management of ventricular arrhythmias (2017 AHA/ACC/HRS)
Study NCT05582044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower-body Negative Pressure (-25 mmHg)
Description: The LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, applying -25mmHg LBNP.
Study NCT05687227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online education and counseling
Description: Online education and counseling regarding gynecological examination
Study NCT04877678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bepotastine
Description: 10 mg Bepotastine, twice a day
Study NCT04877678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical looking placebo, twice a day
Study NCT05582044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower-body Negative Pressure (-25 mmHg)
Description: The LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, applying -25mmHg LBNP.
Study NCT05582044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower-body Negative Pressure (-15 mmHg)
Description: The LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, applying -15mmHg LBNP.
Study NCT05582044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower-body Negative Pressure (-15 mmHg)
Description: The LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, applying -15mmHg LBNP.
Study NCT05582044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower-body Neutral Pressure (0 mmHg)
Description: In this placebo trial, the LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, but the chamber will be vented to atmosphere.
Study NCT05582044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower-body Neutral Pressure (0 mmHg)
Description: In this placebo trial, the LBNP chamber will be sealed at the waist prior to Control measures, and the vacuum system will be activated to coincide with the onset of exercise, but the chamber will be vented to atmosphere.
Study NCT04978051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firazyr
Description: Icatibant 10 MG/ML Prefilled Syringe
Study NCT04978051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SoC
Description: The SoC could include respiratory support measures, fluid therapy, antipyretic treatment, postural measures, low-molecular-weight-heparins, corticosteroids, such as dexamethasone, remdesivir and other therapeutic options
Study NCT06380790 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laser-aided csf
Description: Laser-aided csf before leveling and alignment
Study NCT06380790 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: placebo laser-aided csf
Description: placebo laser-aided csf before leveling and alignment
Study NCT06120959 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stabilization exercise
Description: The exercise program included Bridging, Seated Marching Twist, Quadruped pelvic tilts, Modified Side Plank, and Bird dog for 6 successive weeks. .
Study NCT06120959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stabilization exercise
Description: The exercise program included Bridging, Seated Marching Twist, Quadruped pelvic tilts, Modified Side Plank, and Bird dog for 6 successive weeks. .
Study NCT05031689 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract
Description: Control Group will use SPF 30 sunscreen plus pharmaceutical formulation without green banana peel extract
Study NCT05031689 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SPF 30 sunscreen and pharmaceutical formulation containing green banana peel extract
Description: Study Group In addition to the SPF 30 sunscreen, a pharmaceutical formulation containing green banana peel extract will be used.
Study NCT03952234 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: L-Citrulline
Description: To determine the safest maximum dose of L-Citrulline which could be used as a potential treatment for adults with disorder of energy metabolism called MELAS
Study NCT05372393 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration anaesthesia in carpal tunnel release
Description: The anaesthetic cocktail consists of 1 ml of (7.5%) sodium bicarbonate (Natriumbicarbonate Braun 75mg/ml), 4,5 ml of lidocaine with adrenaline 1% (Lidocain cum adrenalin 10 mg/ml), 4,5 ml of bupivacaine with adrenaline 0.5% (Marcain cum adrenalin 5mg/ml +5 µg/ml). The anaesthetic cocktail must be prepared in the above-mentioned order to avoid possible precipitation. A 24-gauge hypodermic needle and 10 ml syringe are used to inject the solution. The care provider pinches from the area of median nerve blockade prior to performing local anaesthesia. All the anaesthetic solution is injected locally. Additional anaesthetic solution can be injected locally if necessary.
Study NCT05372393 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal median nerve block with local infiltration anaesthesia in carpal tunnel release
Description: The anaesthetic cocktail consists of 1 ml of (7.5%) sodium bicarbonate (Natriumbicarbonate Braun 75mg/ml), 4,5 ml of lidocaine with adrenaline 1% (Lidocain cum adrenalin 10 mg/ml), 4,5 ml of bupivacaine with adrenaline 0.5% (Marcain cum adrenalin 5mg/ml +5 µg/ml). The anaesthetic cocktail must be prepared in the above-mentioned order to avoid possible precipitation. A 24-gauge hypodermic needle and 10 ml syringe are used to inject the solution. Half of the anaesthetic solution is injected into the median nerve area 5-7 cm proximally from the distal wrist crease. The other half is injected locally. Additional anaesthetic solution can be injected locally if necessary.
Study NCT04831437 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated EBRT
Description: EBRT dose of 40Gy in 15 fractions over 3 weeks plus 3 weekly infusions of cisplatin 40mg/m2
Study NCT04831437 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard EBRT
Description: EBRT dose of 45Gy in 25 fractions over 5 weeks plus 5 weekly infusions of cisplatin 40mg/m2
Study NCT04187131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: augmented reality
Description: The participants will be wearing an EEG cap and Augmented Reality headset (AR-based EEG-guided system) for 10 sessions with a licensed occupational therapist, provided in addition to usual rehabilitation care (either in inpatient rehabilitation or at home). These sessions will focus on activities of daily living that the participants want to practice. All sessions will last approximately 1 hour. These sessions will be scheduled around the existing therapy schedule to cause the least amount of interference with planned clinical activities.
Study NCT05547386 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT scan
Study NCT05547386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 Gozetotide
Description: Given IV
Study NCT05547386 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan
Study NCT06120959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor exercise
Description: The pelvic floor exercise protocol involved several steps. Prior to commencing the exercise, women were instructed to empty their bladders. The initial position for the woman was lying in a crook lying position. They were then guided to contract and hold their pelvic muscles for a duration of 5 to 6 seconds, followed by a relaxation period of 5 to 6 seconds. As the sessions progressed, patients were encouraged to perform the exercises in different positions: from a quadriped position, then sitting, followed by standing, and eventually while walking. Each session had a duration of 20 minutes, and the recommended frequency was three times a week for a span of 6 weeks. The repetitions were set at 10 to 15 per set, with two sets in total.
Study NCT05541523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioural therapy
Description: The three therapists in the cognitive behavioural group therapy condition were two students of master's degree of nursing with formal education in cognitive therapy and one psychological specialist nurse working in a palliative care unit. There was no evidence of significant deviation from the protocol.
Study NCT05541523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness-based therapy
Description: The two therapists in the mindfulness-based stress reduction condition were one clinical psychologist and one student of master's degree of nursing with formal education in mindfulness.Both interventions were manualized. To assure adherence to the study protocol meetings between the therapists and the researchers were organized regularly and the therapists detailed the content of each group session in clinical records which were frequently monitored by a research assistant.
Study NCT06402968 — intervention group
Intervention type: DRUG
Intervention: Clevidipine Injection
Description: Sites will be trained and instructed to administer IV clevidipine according to Food and Drug Administration label, which recommends starting at 1-2 mg/hour, and then doubling the dose initially at short (90 second) intervals. As the BP approaches the goal, the increase in doses should be less than doubling and the time between dose adjustments should be lengthened to every 5-10 minutes. The desired therapeutic response for most patients occurs at doses of 4-6 mg/hour. Most patients have been treated with maximum doses of 16 mg/hour or less. There is limited short-term experience with doses up to 32 mg/hour, and because of lipid load restrictions, no more than 1000 mL or an average of 21 mg/hour of Clevidipine infusion is recommended per 24-hour period. There is little experience beyond 72 hours at any dose.
Study NCT06402968 — intervention group
Intervention type: DRUG
Intervention: Alternate IV Antihypertensive Regimen
Description: The alternate IV antihypertensive regimen would be the institutional standard management at designated non-clevidipine hospitals. It is expected that most of these sites will be using IV nicardipine, which if administered per FDA label is started at 5 mg/hour and increased by 2.5 mg/hour every 5-15 minutes to a maximum dose of 15mg/hour, until desired BP is reached. Once the goal is reached, then the dose may be reduced to 3 mg/hour.
Study NCT04945213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biperiden
Description: 5mg of biperiden diluted in 100 ml of 0.9% saline - every 6 hours for 10 consecutive days - IV
Study NCT04945213 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1ml sterile vehicle (sodium lactate, lactic acid, sodium hydroxide and water for injections) diluted in 100 ml 0.9% saline - every 6 hours for 10 consecutive days - IV
Study NCT05289206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vaccine - ChAdOx1-S/nCoV-19 [recombinant]
Description: ChAdOx1-S/nCoV-19 \[recombinant\] - 0.5 mL single dose, intramuscular in deltoid, with an interval of 180 days (+/- 30 days) from the 2nd dose of the initial vaccination schedule with CoronaVac
Study NCT04685499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBP-301
Description: Telomerase-specific Type 5 Adenovirus. OBP-301 OBP 301 will be injected intratumorally into tumor lesions.
Study NCT04685499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Standard dose pembrolizumab 200 mg IV every 3 weeks for up to one year
Study NCT05836129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) practice
Description: See previous description
Study NCT05836129 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stress reduction class (online)
Description: See previous description
Study NCT05108688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine
Description: Mirtazapine 30 mg tablet once daily for 3 successive days
Study NCT05108688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan
Description: Sumatriptan 50 mg tablet once daily for 3 successive days
Study NCT05108688 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets once daily for 3 successive days.
Study NCT05161182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat, low carbohydrate diet
Description: Throughout the 5-day intervention, participants are provided with a high fat, low carbohydrate (HF-LC) diet in which the percentage of fat, protein and carbohydrate is 60%, 15% and 25%, respectively.
Study NCT05161182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fat, high carbohydrate diet
Description: Throughout the 5-day intervention, participants are provided with a low fat, high carbohydrate (LF-HC) diet in which the percentage of fat, protein and carbohydrate is 10%, 15% and 75%, respectively.
Study NCT05295745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy and multidisciplinary intervention
Description: The Randomized Controlled Trial will comprise of multidisciplinary intervention and remediation cognitive therapy which will be conducted with obese diagnosed adults of 19-60 years old. The enrolled patients will be randomized in a two-arm control trial with repeated measures and follow-up of three months. The experimental group participants will receive the intervention, while the control group remains on a waiting list.~Nutritional and physical activity plus cognitive remediation therapy sessions to improve the thoughts style, problem-solving, planning and organization, the emotions and body image are included
Study NCT05454397 — intervention group
Intervention type: OTHER
Intervention: Observational study, no intervention
Description: Observational study, no intervention